Related Experiment Video
Updated: Jun 30, 2026

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development
Published on: June 15, 2017
Arsenic trioxide phosphorylates c-Fos to transactivate p21(WAF1/CIP1) expression
Zi-Miao Liu1, Huei-Sheng Huang
1Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Abstract:
An infamous poison, arsenic also has been used as a drug for nearly 2400 years; in recently years, arsenic has been effective in the treatment of acute promyelocytic leukemia. Increasing evidence suggests that opposite effects of arsenic trioxide (ATO) on tumors depend on its concentrations. For this reason, the mechanisms of action of the drug should be elucidated, and it should be used therapeutically only with extreme caution. Previously, we demonstrated the opposing effects of ERK1/2 and JNK on p21(WAF1/CIP1) (p21) expression in response to ATO in A431 cells. In addition, JNK phosphorylates c-Jun (Ser(63/73)) to recruit TGIF/HDAC1 to suppress p21 gene expression. Presently, we demonstrated that a high concentration of ATO sustains ERK1/2 phosphorylation, and increases c-Fos biosynthesis and stability, which enhances p21 gene expression. Using site-directed mutagenesis, a DNA affinity precipitation assay, and functional assays, we demonstrated that phosphorylation of the C-terminus of c-Fos (Thr(232), Thr(325), Thr(331), and Ser(374)) plays an important role in its binding to the p21 promoter, and in conjunction with N-terminus phosphorylation of c-Fos (Ser(70)) to transactivate p21 promoter expression. In conclusion, a high concentration of ATO can sustain ERK1/2 activation to enhance c-Fos expression, then dimerize with dephosphorylated c-Jun (Ser(63/73)) and recruit p300/CBP to the Sp1 sites (-84/-64) to activate p21 gene expression in A431 cells.
Insights
High concentrations of arsenic trioxide (ATO) activate ERK1/2, boosting c-Fos and enhancing p21 gene expression by forming a complex with c-Jun and p300/CBP. This clarifies ATO
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Arsenic trioxide (ATO) has a dual role as a poison and a therapeutic agent, particularly in treating acute promyelocytic leukemia.
- ATO's anti-tumor effects are concentration-dependent, necessitating a thorough understanding of its mechanisms of action for safe therapeutic use.
- Previous research indicated opposing roles of ERK1/2 and JNK pathways in regulating p21(WAF1/CIP1) (p21) expression under ATO treatment in A431 cells.
Purpose of the Study:
- To elucidate the concentration-dependent mechanisms of arsenic trioxide (ATO) in regulating gene expression.
- To investigate the role of high-concentration ATO in sustaining ERK1/2 phosphorylation and its downstream effects on c-Fos and p21 gene expression.
- To determine the specific phosphorylation sites on c-Fos crucial for its interaction with the p21 promoter.
Main Methods:
- Utilized site-directed mutagenesis to identify critical phosphorylation sites on c-Fos.
- Employed DNA affinity precipitation assays to assess the binding of c-Fos to the p21 promoter.
- Conducted functional assays to evaluate the transactivation of p21 gene expression.
Main Results:
- High concentrations of ATO sustain ERK1/2 phosphorylation, leading to increased c-Fos biosynthesis and stability.
- Phosphorylation of specific C-terminal (Thr232, Thr325, Thr331, Ser374) and N-terminal (Ser70) sites on c-Fos is essential for its binding to the p21 promoter.
- This interaction, along with dimerized dephosphorylated c-Jun, recruits p300/CBP to the Sp1 sites, activating p21 gene expression.
Conclusions:
- High-concentration ATO activates the ERK1/2 pathway, enhancing c-Fos expression and subsequent p21 gene transactivation in A431 cells.
- The study identifies key phosphorylation events in c-Fos that mediate its interaction with the p21 promoter.
- These findings provide critical insights into the molecular mechanisms underlying ATO's therapeutic effects and highlight the importance of concentration-specific actions.
More Related Videos
Related Concept Videos
Anaphase Promoting Complex
Cell Specific Gene Expression
MAPK Signaling Cascades
Inhibition of Cdk Activity
RNA Polymerase II Accessory Proteins
Positive Regulator Molecules

